肿瘤坏死因子相关凋亡诱导配体在血管瘤组织和血清中的表达及其临床意义  

Expression and clinical significance of TRAIL in both tissue and serum of hemangiomas

作　　者：王琪影[1] 刘林皤[1] 牛扶幼[1] 翟晓梅[1] 

机构地区：[1]郑州大学第一附属医院整形外科,450052

出　　处：《中华实验外科杂志》2007年第8期1002-1003,共2页Chinese Journal of Experimental Surgery

摘　　要：目的探讨肿瘤坏死因子相关凋亡诱导配体(TRAIL)在血管瘤组织和血清中的表达水平及其临床意义。方法应用免疫组织化学法和流式细胞术检测增生期、消退期血管瘤组织中TRAIL蛋白的表达,应用酶联免疫吸附试验检测血清可溶性TRAIL(sTRAIL)的含量,分别以20例正常皮肤组织和20例健康人血清作为对照。结果组织中TRAIL蛋白相对含量在增生期、消退期血管瘤及对照组分别为1.25±0.40、1.75±0.58和1.00±0.23,各组之间比较差异有统计学意义(P<0.05)。血清中sTRAIL的含量在三组分别为(1490.06±356.56)、(1658.80±371.42)和(956.86±268.62)ng/L,在血管瘤各期较对照组均明显升高,差异有统计学意义(P<0.05),但在血管瘤两期之间差异无统计学意义(P>0.05)。结论血管瘤组织中TRAIL与血清中sTRAIL的表达不完全一致。血管瘤不同时期组织中TRAIL蛋白的表达差异有助于血管瘤的分期诊断。Objective To investigate the expression and clinical significance of tumor necrosis factor-related apoptosis- inducing ligand （TRAIL） in both tissue and serum of hemangiomas. Methods Immunohistochemical staining and flow cytometry were applied to detect the expression of TRAIL in proliferating and involuting phase of hemangiomas. The concentration of soluble TRAIL （sTRAIL） in serum was detected by ELISA. Twenty cases of normal skin tissue and 20 cases of serum from healthy people served as the controls respectively. Results The expression of TRAIL in tissue in the proliferating phase, involuting phase of hemangiomas and the control group was 1.25 ± 0.40,1.75 ± 0.58 and 1.00 ± 0.23 respectively. There was significant difference among three groups （ P 〈 0.05 ）. The concentration of sTRAIL in serum in three groups was （1490.06 ±356.56） ,（1658.80 ±371.42） and （956.86 ±268.62） ng/L respectively, significantly higher in serum of hemangiomas than in control group （P 〈 0.05 ）, while there was no significant difference in serum sTRAIL between two phases of hemangiomas （P 〉 0.05 ）. Conclusion TRAIL in tumor tissue was not exactly accorded with sTRAIL in serum of hemangioma. TRAIL in tumor tissue might be involved in analyzing different phases of hemangiomas.

关 键 词：血管瘤 肿瘤坏死因子 血清 

分 类 号：R732.2[医药卫生—肿瘤]